Emyria Ltd (AU:EMD) has released an update.
Emyria Ltd has received endorsement from the ACT Health Ethics Committee for its psilocybin-assisted therapy program, aimed at treating patients with treatment-resistant depression. This positions Emyria as a leader in offering both MDMA- and psilocybin-assisted therapies, expanding its innovative mental health treatment options. With anticipated approval from the Therapeutic Goods Administration, Emyria is set to enhance care for complex mental health conditions.
For further insights into AU:EMD stock, check out TipRanks’ Stock Analysis page.